modelLamivudine
Extends from Pharmacolibrary.Drugs.ATC.J.J05AF05.
Information
| name: | Lamivudine | |
| ATC code: | J05AF05 | route: | oral |
| compartments: | 1 | |
| dosage: | 150 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 0.32 | L/h/kg |
| other parameters in model implementation | ||
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV infection and hepatitis B virus (HBV) infection. It is an approved antiviral drug widely used as part of combination therapy for HIV/AIDS and also for chronic HBV infection.
Pharmacokinetics
Pharmacokinetics in healthy adult volunteers after oral administration.
References
Wen, H, et al., & Zhang, L (2022). Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. Expert review of clinical pharmacology 15(5) 647–655. DOI:10.1080/17512433.2022.2078306 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35938476
Bekker, A, et al., & Cressey, TR (2024). Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study. The Journal of antimicrobial chemotherapy 79(10) 2570–2574. DOI:10.1093/jac/dkae259 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39092932
Moore, KH, et al., & Bartlett, JA (1999). Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrobial agents and chemotherapy 43(12) 3025–3029. DOI:10.1128/AAC.43.12.3025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10582904
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)